Overview

GBM Personalized Trial

Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.
Phase:
Early Phase 1
Details
Lead Sponsor:
AHS Cancer Control Alberta
Treatments:
Afatinib
Dasatinib
Everolimus
Olaparib
Palbociclib